News and Trends 20 Nov 2017
After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy
DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […]